SCHEMBL635573

SCHEMBL635573

CCN1CCN(c2cccc3c2CN([C@H](CCCCOS(C)(=O)=O)c2ccc(OC)c(OC)c2)C3=O)CC1

nearest known ligand 0.68

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 19/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL635086 0.98 UTS2R (0.69) UTS2R
SCHEMBL8101797 0.98 UTS2R (0.69) UTS2R
SCHEMBL635888 0.88 UTS2R (0.70) UTS2R
SCHEMBL635889 0.88 UTS2R (0.70) UTS2R
SCHEMBL2343966 0.87 UTS2R (0.71) UTS2R
SCHEMBL635170 0.87 UTS2R (0.71) UTS2R
SCHEMBL635171 0.87 UTS2R (0.71) UTS2R
SCHEMBL2346047 0.86 UTS2R (0.68) UTS2R
SCHEMBL2345910 0.86 UTS2R (0.76) UTS2R
SCHEMBL2345909 0.86 UTS2R (0.72) UTS2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9079896-B2 Urotensin II receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 US disclosed
EP-2326644-B1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2012-02-22 EP disclosed
EP-2326644-A1 UROTENSIN II RECEPTOR ANTAGONISTS Janssen Pharmaceutica N.V. (BE) 2011-06-01 EP disclosed
WO-2010017105-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-11 WO disclosed
US-20100029616-A1 UROTENSIN II RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029616-A1 UROTENSIN II RECEPTOR ANTAGONISTS UTS2R, PLAUR, BDKRB2 UTS2R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.